Author

Mengchen Qian

Observed names: M. Qian, Qian, Mengchen

Institutions: Daiichi Sankyo (United States), Huazhong University of Science and Technology

Observed institutions: Daiichi Sankyo (United States), Huazhong University of Science and Technology

OpenAlex ID: A5061412157

453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study

2022 · T. Doi, M. Patel, et al. · Annals of Oncology · 44

OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study

2023 · M. Johnson, M. Awad, et al. · Journal of Thoracic Oncology · 42

610O Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6

2024 · M.R. Patel, E.P. Hamilton, et al. · Annals of Oncology · 21

1787P Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study

2024 · M.L. Johnson, P.F. Simoes da Rocha, et al. · Annals of Oncology · 5

2760MO Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDeate-Lung01

2025 · P.F. Simoes da Rocha, Y.J. Kim, et al. · Annals of Oncology · 4

1550TiP Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)

2022 · L. Paz-Ares, M.L. Johnson, et al. · Annals of Oncology · 3

P1.13A.12 Exposure-Response Analyses to Support Ph3 Dose Selection for I-Dxd (Ifinatamab Deruxtecan) in Extensive Stage SCLC Patients

2024 · N.M. Midde, S. Hennig, et al. · Journal of Thoracic Oncology · 1

Toward Recursive Self-Improvement in Physical AI

2026 · Luo, Meng, Bai, Zechen, et al. · arXiv (Cornell University)

PS3-4 Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: Japanese subgroup analysis from IDeate-Lung01

2026 · H. Hayashi, T. Sakai, et al. · Annals of Oncology

When Evidence Shapes Collaboration: Knowledge-Conditioned Topology Generation for Multi-Agent Systems

2026 · Yangxiao Jiang, Jiarun Fan, et al. · Findings of the Association for Computational Linguistics: EMNLP (Findings of EMNLP)

RIDGE: Region-Informed Derivative-Guided Evidence Selection for Long Video Understanding

2026 · Shanqing Xu, Meng Luo, et al. · Findings of the Association for Computational Linguistics: EMNLP (Findings of EMNLP)

OmniHallu: Unified Hallucination Detection for Cross-Modal Comprehension and Generation in Multimodal Large Language Models

2026 · Jianjiang Yang, LI Peihang, et al. · Findings of the Association for Computational Linguistics: EMNLP (Findings of EMNLP)

OA06.03 Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Study

2025 · M.-J. Ahn, M.L. Johnson, et al. · Journal of Thoracic Oncology

Works count: 13

Citation count: 120

H-index: 4

I10-index: 3